CASI Pharmaceuticals (CASIF) Cost of Revenue (2022 - 2025)

CASI Pharmaceuticals has reported Cost of Revenue for 4 years, with the latest figure at $3.5 million in Q4 2025.

• For the quarter ending Q4 2025, Cost of Revenue fell 65.16% year-over-year to $3.5 million; the trailing twelve-month figure through Dec 2025 stood at $10.6 million (down 38.84% YoY), and the FY2025 full-year result was $10.6 million, down 38.84% from the prior year.
• Cost of Revenue for Q4 2025 stood at $3.5 million, up from $2.4 million in the prior quarter.
• The five-year high for Cost of Revenue was $10.1 million in Q4 2024, with the low at $1.6 million in Q1 2024.
• Historically, Cost of Revenue has averaged $3.6 million across 4 years, with a median of $3.5 million in 2022.
• Annual changes were most pronounced in 2024 — Cost of Revenue surged 259.79% — and 2025, when it slumped 65.16%.
• CASI Pharmaceuticals' Cost of Revenue stood at $4.3 million in 2022, then plunged by 34.11% to $2.8 million in 2023, then surged by 259.79% to $10.1 million in 2024, then tumbled by 65.16% to $3.5 million in 2025.
• The last three Cost of Revenue figures came in at $3.5 million (Q4 2025), $2.4 million (Q3 2025), and $2.1 million (Q2 2025), per Business Quant data.